NRXP logo

NRXP
NRX Pharmaceuticals Inc

13,246
Mkt Cap
$97.55M
Volume
3,933.00
52W High
$3.84
52W Low
$1.62
PE Ratio
-1.89
NRXP Fundamentals
Price
$2.97
Prev Close
$2.95
Open
$3.04
50D MA
$2.07
Beta
1.16
Avg. Volume
836,678.46
EPS (Annual)
-$1.34
P/B
-5.91
$50.83
Loading...
Loading...
News
all
press releases
NRx Pharmaceuticals' (NRXP) Buy Rating Reiterated at D. Boral Capital
D. Boral Capital restated a "buy" rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a research note on Monday...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from Analysts
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are currently covering the stock, MarketBeat reports. One...
MarketBeat·11d ago
News Placeholder
NRx Pharmaceuticals' (NRXP) Buy Rating Reaffirmed at D. Boral Capital
D. Boral Capital reiterated a "buy" rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research report on Tuesday...
MarketBeat·30d ago
News Placeholder
NRx Pharmaceuticals (NASDAQ:NRXP) Receives "Buy" Rating from BTIG Research
BTIG Research reaffirmed a "buy" rating and set a $25.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday...
MarketBeat·30d ago
News Placeholder
NRx Pharmaceuticals (NASDAQ:NRXP) Releases Earnings Results, Beats Expectations By $0.28 EPS
NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) posted its earnings results on Monday. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.28...
MarketBeat·30d ago
News Placeholder
NRx Pharmaceuticals Q4 Earnings Call Highlights
NRx Pharmaceuticals (NASDAQ:NRXP) executives used the company's fourth-quarter 2025 results call to outline what they described as a "pivotal and transformative" year, highlighting advancing regulatory pathways for preservative-free ketamine and an investigational ketamine product, as well as an exp...
MarketBeat·30d ago
News Placeholder
NRx Pharmaceuticals Wraps Virtual Annual Meeting, Eyes Pivotal 2025 Earnings Call Ahead
NRx Pharmaceuticals (NASDAQ:NRXP) held its 2025 annual meeting of stockholders in a virtual format, with Chairman Jonathan Javitt calling the meeting to order at 10:00 a.m. Eastern. Javitt said the company hopes to hold future meetings in person "now that we have clinical facilities open," adding th...
MarketBeat·1mo ago
News Placeholder
NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates
NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of +323.53% and -84.40%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
NRx Pharmaceuticals' (NRXP) "Buy" Rating Reaffirmed at D. Boral Capital
D. Boral Capital reiterated a "buy" rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a report on Monday...
MarketBeat·1mo ago
News Placeholder
NRx Pharma Stock Jumps After FDA Signals Path To NDA For Ketamine Depression Drug
The FDA signals its willingness to review NRx Pharmaceuticals' NRX-100 NDA, boosting optimism around its depression treatment.read more...
Benzinga·1mo ago
<
1
2
...
>

Latest NRXP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.